


DO NOT ENTER: /ESO/

PATENT APPLN. NO. 10/562,059
RESPONSE UNDER 37 C.F.R. § 1.116RECEIVED
CENTRAL FAX CENTERPATENT
FINAL

MAR 09 2009

IN THE CLAIMS:

1. (canceled)
2. (currently amended) An asparagine-linked disialoundecaoligosaccharide-fatty acid amide[[,]] which does not have an amino acid other than the asparagine, wherein the disialoundecaoligosaccharaide has the formula:



and wherein the fatty acid is one having 8 to 24 carbon atoms.

3. (original) An asparagine-linked disialoundecaoligosaccharide-fatty acid amide according to claim 2 wherein the fatty acid is one having 10 to 22 carbon atoms.

PATENT APPLN. NO. 10/562,059
RESPONSE UNDER 37 C.F.R. § 1.116

PATENT
FINAL

4. (original) An asparagine-linked disialoundecaoligosaccharide-fatty acid amide according to claim 3 wherein the fatty acid is at least one selected from the group consisting of capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachic acid, behenic acid and oleic acid.

5. (currently amended) A composition comprising asparagine-linked disialoundecaoligosaccharide-fatty acid amide of [[,]] claim 2 and a pharmaceutical additive.


6. (original) A composition according to claim 5 wherein the pharmaceutical additive is at least one selected from the group consisting of lactose, glycerin, glucose, sucrose and mannitol.

7. (previously presented) A drug containing the asparagine-linked disialoundecaoligosaccharide-fatty acid amide of claim 2.

8. (currently amended) A drug comprising at least one selected from asparagine-linked disialoundecaoligosaccharide-fatty acid amide of claim 2, ~~wherein the fatty acid is one having 8 to 24 carbon atoms,~~ and asparagine-linked disialoundecaoligosaccharide having formula (3): [[,]]

PATENT APPLN. NO. 10/562,059
RESPONSE UNDER 37 C.F.R. § 1.116

PATENT
FINAL



and a pharmaceutical additive.

9-11. (canceled)

12. (previously presented) A composition comprising asparagine-linked disialoundecaoligosaccharide-fatty acid amide of claim 3, and a pharmaceutical additive.

13. (previously presented) A composition comprising asparagine-linked disialoundecaoligosaccharide-fatty acid amide of claim 4, and a pharmaceutical additive.

PATENT APPLN. NO. 10/562,059
RESPONSE UNDER 37 C.F.R. § 1.116

PATENT
FINAL

14. (canceled)

15. (previously presented) A composition according to claim 12 wherein the pharmaceutical additive is at least one selected from the group consisting of lactose, glycerin, glucose, sucrose and mannitol.

16. (previously presented) A composition according to claim 13 wherein the pharmaceutical additive is at least one selected from the group consisting of lactose, glycerin, glucose, sucrose and mannitol.

17-20. (canceled)

21. (new) A method of treating viral infection comprising administering a therapeutically effective amount of an asparagine-linked disialoundecaoligosaccharide-fatty acid amide of claim 2 to a subject in need of such treatment.

22. (new) A method of treating viral infection comprising administering a therapeutically effective amount of an asparagine-linked disialoundecaoligosaccharide-fatty acid amide of

PATENT APPLN. NO. 10/562,059
RESPONSE UNDER 37 C.F.R. § 1.116

PATENT
FINAL

claim 3 to a subject in need of such treatment.

23. (new) A method of treating viral infection comprising administering a therapeutically effective amount of an asparagine-linked disialoundecaoligosaccharide-fatty acid amide of claim 4 to a subject in need of such treatment.

24. (new) A method of treating viral infection comprising administering a therapeutically effective amount of a composition of claim 5 to a subject in need of such treatment.

25. (new) A method of treating viral infection comprising administering a therapeutically effective amount of a composition of claim 6 to a subject in need of such treatment.

26. (new) A method of treating viral infection comprising administering a therapeutically effective amount of a composition of claim 12 to a subject in need of such treatment.

27. (new) A method of treating viral infection comprising administering a therapeutically effective amount of a composition of claim 13 to a subject in need of such treatment.

PATENT APPLN. NO. 10/562,059
RESPONSE UNDER 37 C.F.R. § 1.116

PATENT
FINAL

28. (new) A method of treating viral infection comprising administering a therapeutically effective amount of a composition of claim 15 to a subject in need of such treatment.

29. (new) A method of treating viral infection comprising administering a therapeutically effective amount of a composition of claim 16 to a subject in need of such treatment.

30. (new) A method of treating viral infection comprising administering a therapeutically effective amount of a drug of claim 7 to a subject in need of such treatment.

31. (new) A method of treating viral infection comprising administering a therapeutically effective amount of a drug of claim 8 to a subject in need of such treatment.